Navigation Links
Primary biliary cirrhosis more severe in African-American and Hispanic patients
Date:9/5/2007

Non-Caucasian patients seeking medical care for primary biliary cirrhosis have more severe liver disease compared to Caucasian patients, a new study has found. The reasons for this disparity are not clear, say the authors. These findings are in the September issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

Primary biliary cirrhosis is an uncommon liver disease that typically afflicts Caucasian women between ages 30 and 60, so there is little data available on how it affects non-Caucasian patients. To shed light on this topic, researchers led by Marion Peters of the University of California in San Francisco set out to examine differences in disease severity among patients of various racial and ethnic groups.

They studied 535 individuals with primary biliary cirrhosis who were screened for possible enrollment into a large, national multicenter clinical trial of ursodeoxycholic acid with or without weekly methotrexate, between April, 1989 and January, 1998. For each patient, they collected demographic information, clinical symptoms, physical findings and laboratory test results. They then examined differences between ethnic groups, genders, and anti-mitochondrial antibody (AMA) status. They also compared the 265 patients who entered the trial to those who did not.

The majority of the patients considered for the trial were Caucasian (86.4 percent). Just 7.9 percent were Hispanic, and 3.9 percent were African-American. Still, the researchers noticed significant differences between Caucasian and non-Caucasian patients. Non-Caucasians appeared to have significantly more severe liver disease than Caucasians, as assessed by history, physical examination and laboratory featu
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Page: 1 2

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. Is caries in primary and permanent tooth related?
3. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
4. Shortage Of Funds In Primary Care Trust In UK
5. What Will Primary Care Look Like In England by 2015?
6. Primary Health Care MoU Signed on the Sidelines of the PBD
7. Primary Care centers to provide out patient treatment
8. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
9. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
10. Gene That Causes Metastasis of the Primary Tumor, Identified
11. IMA To Train Doctors In Primary Treatment Of HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2008)...Milk Mustache Campaign and Everyday Food Team ... WASHINGTON, May 22 /PRNewswire/ -- America, star...k Mustache Campaign and Everyday Food magazine,are...onor of June Dairy,Month., Whether it,s a sweet t...smoothie aficionados seeking a taste of fame are i...
(Date:5/22/2008)...ntal drug has blocked the progression of prostate ...of the disease, new research shows. , The agent, ... histone deacetylase (HDAC) inhibitors, compounds ... against cancer but are turned off by the cancer p...University Comprehensive Cancer Center researchers...
(Date:5/22/2008)...rch Foundation recently awarded its top honors to ...at the 2008 Spring Research Review Awards Dinner. ...ence was established in 1974 by the actress Dina M...e highest honor JDRF awards, and is presented annu...d commitment to diabetes research and for their se...
(Date:5/22/2008)...swire-USNewswire/ -- Many baby boomers,incorrectly...ccording to a,new survey conducted by Harris Inter...Plans (AHIP). Most say that disability insurance i...lf say they do not have any disability,income prot...rnh/20040830/AHIPLOGO ), "Baby boomers recognize...
Breaking Medicine News(10 mins):Health News:Thirsting for Healthful Smoothie Recipes That 'got milk?' 2Health News:Experimental agent blocks prostate cancer in animal study 2Health News:JDRF announces 2008 Spring Research Review Award 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 3
...ppear five times as likely as lean women to have p...es fertility and contributes to other// illnesses,...f Archives of Internal Medicine, one of the JAMA/A...ndrome occurs when the ovaries malfunction and lev...
...tric inpatient services, which will transfer from ...urpose-built facility will include 16 individual c...ll also include "bedside beds" for parents and a n...which is part of the plan to centralize children's...
...e to screen six-month-old infants for HIV. This in...g babies delivered from HIV infected// women. This...ics and one hospital. It is estimated that among ..., the infection rate as depicted by the Botswana A...
...ation Practices has made the recommendation on Wed...he shingles(herpes zoster) virus.// The vaccine i... approval for its use in May. It has a live virus ...han the children's chicken pox virus, also from Me...
Other Medicine News:Health News:Polycystic Ovary Syndrome More Prevalent in Overweight Women 2
(Date:5/21/2008)...First Presentation of Full Data Set from the TRIUM... Treprostinil, SILVER SPRING, Md., May 21 /PRNews... (Nasdaq: UTHR ) and its wholly-owned subsidiary,... presentations concerning,the treatment of pulmona...ere reported at the American Thoracic Society (ATS...
(Date:5/21/2008)... Innovative pipeline products highlight Watson,s c...oed Until 2:10 PM EDT, ORLANDO, Fla., May 21 /PRN... (NYSE: WPI ), a leading specialty pharmaceutical...nted clinical data on two Phase 3 products at,the ...The abstracts include,a cardiac safety trial invol...
(Date:5/21/2008)... Tumor responses, safety and long-term survivors...h product approach, SAN FRANCISCO and YONGIN-SI, ... (San Francisco, CA and Ottawa, Ontario), and its ...today that Phase I clinical,trial results from its... in,the premier journal Lancet Oncology. The major...
(Date:5/21/2008)... Findings Show Cystic Fibrosis Patients Cough More... -, SOUTH PLAINFIELD, N.J., May 21 /PRNews...ced new data suggesting that the quantification of... outcome measure in cystic,fibrosis (CF). Cough is...related symptoms in CF. According to data presente...
Breaking Medicine Technology:Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 2Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 3Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 4PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 2PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 3PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 4YouTube Video to Benefit AIDS Babies 4653 1CNA Presents New Data on Sutters Medical Redlining 4650 1CNA Presents New Data on Sutters Medical Redlining 4650 2CNA Presents New Data on Sutters Medical Redlining 4650 3Sigma Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 1515 1Sigma Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 1515 2Sigma Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 1515 3Hospital Romance May Largely Be Fiction 4649 1Hospital Romance May Largely Be Fiction 4649 2Hospital Romance May Largely Be Fiction 4649 3
...- Forest,Laboratories, Inc. and PAION AG today ann... In Acute Ischemic Stroke) study with the,compound...,investigate the improvement of clinical outcome i... Desmoteplase within 3 to 9 hours,after onset of s...,efficacy endpoint (difference between active trea...
... Research,collaborators with Oncolytics Biotech In...r presentation covering REOLYSIN(R),clinical trial...,(ASCO) Annual Meeting, to be held June 1-5, 2007 ...tics, U.K. Phase I systemic,administration trial. ... Study of,Wild-Type Oncolytic Reovirus Administere...
Other Medicine Technology:Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
Lumitex® LightMat® Surgical Illuminator improves visualization in deep cavity surgery. Flexible and malleable, it attaches easily to most retractors, bringing bright, cool area lighting where
...HELION family consists of four models in proven ha...ure you find the right solution for every applicat... of two or three mobile lamps also battery-powered...h on the lamp housing, the standard-plus models of...
The Sunnex Celestial Star™ light is ideal for surgical applications. The flexible design allows for easy angling and positioning. The space-saving structure is ideal for many facilities includi
... new small incision surgical light is an industry ... for many surgeons. The DeepSite provides 10,000-f...hes, and can be positioned with one hand at distan...t is not tethered to the surgeon, so it allows tot...
Medicine Products: